Chapter title |
Prospective multicenter trial for the response-adapted treatment of high-grade malignant non-Hodgkin's lymphomas: updated results of the COP-BLAM/IMVP-16 protocol with randomized adjuvant radiotherapy.
|
---|---|
Chapter number | 28 |
Book title |
Annals of Oncology
|
Published in |
Annals of Oncology, February 1991
|
DOI | 10.1007/978-1-4899-7305-4_28 |
Pubmed ID | |
Book ISBNs |
978-1-4899-7294-1, 978-1-4899-7305-4
|
Authors |
Engelhard, M, Meusers, P, Brittinger, G, Brack, N, Dornoff, W, Enne, W, Gassmann, W, Gerhartz, H, Hallek, M, Heise, J, Marianne Engelhard, P. Meusers, G. Brittinger, N. Brack, W. Dornoff, W. Enne, W. Gassmann, H. Gerhartz, M. Hallek, J. Heise, W. Hettchen, D. Huhn, K. Kabelitz, R. Kuse, E. Lengfelder, F. Ludwig, I. Meuthen, H. Radtke, C. Schadeck, C. Schöber, E. Schumacher, W. Siegert, H.-J. Staiger, E. Terhardt, E. Thiel, M. Thomas, T. Wagner, M. G. Willems, W. Wilmanns, T. Zwingers, H. Stein, M. Tiemann, K. Lennert, Engelhard, Marianne, Meusers, P., Brittinger, G., Brack, N., Dornoff, W., Enne, W., Gassmann, W., Gerhartz, H., Hallek, M., Heise, J., Hettchen, W., Huhn, D., Kabelitz, K., Kuse, R., Lengfelder, E., Ludwig, F., Meuthen, I., Radtke, H., Schadeck, C., Schöber, C., Schumacher, E., Siegert, W., Staiger, H.-J., Terhardt, E., Thiel, E., Thomas, M., Wagner, T., Willems, M. G., Wilmanns, W., Zwingers, T., Stein, H., Tiemann, M., Lennert, K. |
Abstract |
In a prospective multicenter trial the efficiency of the response-adapted COP-BLAM/IMVP-16 protocol to induce complete remissions (CR) in high-grade malignant non-Hodgkin's lymphomas as well as the prognostic relevance of adjuvant radiotherapy were investigated. From 1986-1989, 548 patients (median age 56 years) with stage II-IV (Ann Arbor) disease were treated with five cycles of COP-BLAM followed by two cycles of IMVP-16. If only a partial remission was obtained at the time of first restaging (RS) after three cycles (delayed response), treatment was switched to IMVP-16 (two to five courses) immediately. Patients achieving CR by the second RS after chemotherapy were randomized to adjuvant radiotherapy or observation. Responses to chemotherapy were 63% CR in patients completing the second RS (N = 350) or 72% if patients achieving late CR by consolidating radiotherapy are added; responses were 58% or 65% if all deaths prior to the second RS are included (N = 50). Overall and relapse-free survival were 71% and 68% at one year and 63% and 61% at two years. Multivariate risk factor analysis proved the early (by first RS) CR response to possess predominant prognostic relevance for survival. A significant advantage of adjuvant radiotherapy over no further treatment for duration of CR is not yet discernible. These results emphasize the importance of a rapidly achieved CR, thus contributing to the design of future trials. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 6 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 2 | 33% |
Student > Bachelor | 1 | 17% |
Student > Doctoral Student | 1 | 17% |
Unknown | 2 | 33% |
Readers by discipline | Count | As % |
---|---|---|
Psychology | 1 | 17% |
Sports and Recreations | 1 | 17% |
Neuroscience | 1 | 17% |
Medicine and Dentistry | 1 | 17% |
Unknown | 2 | 33% |